4109 Share Price Performance
NT$15.55
-14.30 (-47.91%)
Price NT$15.55
Share PriceNT$15.55
4109 Community Narratives
There are no narratives available yet.
Recent 4109 News & Updates
No updates
Jia Jie Biomedical Co., Ltd. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- 1.78
- Gross Margin
- 33.38%
- Net Profit Margin
- 41.48%
- Debt/Equity Ratio
- 0.2%
Jia Jie Biomedical Co., Ltd. Competitors
About 4109
- Founded
- 1995
- Employees
- n/a
- CEO
- WebsiteView website
Jia Jie Biomedical Co., Ltd. produces and sells health foods in Taiwan and Mainland China. It operates through two segments: Nutritional Health Products and Insurance Brokerage. The company engages in the processing, sale, and trading of softshell turtle food; manufacture of dairy products; miscellaneous food manufacturing, such as softshell turtle egg powder capsules, enzyme powder, tortoise jelly, softshell turtle oil, and powder capsules; and import and export, distribution, bidding, quotation of the products. It also involved in the wholesale of nonalcoholic beverages, candy, baked food, supplementary food, groceries, daily commodities, and cosmetics; production of water purification equipment and related parts; life and property insurance brokerage business; development and production of aquatic product technology; and development of biological products. The company was formerly known as Murad Chia Jei Biotechnology Co., Ltd. and changed its name to Jia Jie Biomedical Co., Ltd. in June 2019. Jia Jie Biomedical Co., Ltd. was founded in 1995 and is based in Kaohsiung, Taiwan.
Taiwanese Market Performance
- 7 Days: 0.1%
- 3 Months: 13.7%
- 1 Year: 8.7%
- Year to Date: 2.1%
The market has been flat in the last week, however the Energy sector is down 8.6%. As for the longer term, the market has risen 8.7% in the past 12 months. Looking forward, earnings are forecast to grow by 13% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading